Moreover, some patients suffering from BRAF-mutated melanoma and treated with anti-BRAF compounds exhibit resistance to the treatment by reactivation of the MEK/ERK pathway through MAP3K8/TPL-2/COT accumulation14, 17. The gene discussed is MAP2K7; the disease is melanoma.